{"schema_version":"secwatch.filing_event.v1","accession":"0001789769-26-000018","form_type":"8-K","ticker":"TIL","cik":"0001789769","company_name":"Instil Bio, Inc.","filed_at":"2026-03-27T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.189908+00:00","generated_at":"2026-05-15T08:40:23.453374+00:00","sec_items":["2.02","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Instil Bio discontinues AXN-2510, pivots to acquisitions; cash $76.3M","bullets":["Discontinued clinical development of AXN-2510; terminated license with ImmuneOnco.","Cash, equivalents & marketable securities $76.3M as of Dec 31, 2025, down from $115.1M year-end 2024.","Management evaluating acquisitions and in-licensing opportunities across therapeutic areas.","Net loss per share (GAAP) $1.21 for Q4 2025; full year net loss $10.70 per share.","Cash expected to fund operating plan beyond 2027."],"urls":{"canonical":"https://secwatch.observer/filing/0001789769-26-000018","json":"https://secwatch.observer/filing/0001789769-26-000018.json","markdown":"https://secwatch.observer/filing/0001789769-26-000018.md","text":"https://secwatch.observer/filing/0001789769-26-000018.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1789769/000178976926000018/0001789769-26-000018-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1789769/000178976926000018/til-20260327.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T08:40:23.453374+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"83de90ba09b68917844981ed0f7ac42d125664e6","claim":"Instil Bio, Inc. reported the fourth quarter and full year ended December 31, 2025 results: net income Net loss per share, basic and diluted was $1.21 and $10.70 for the fourth quarter and full year ended December 31, 2025,, EPS Net loss per share, basic and diluted was $1.21 and $10.70 for the fourth quarter and full year ended December 31, 2025,.","evidence_excerpt":"On March 27, 2026, Instil Bio, Inc. (the “Company”) issued a press release providing a corporate update and announcing its financial results for the fourth quarter and full year ended December 31, 2025","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1789769/000178976926000018/0001789769-26-000018-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and full year ended December 31, 2025"},{"label":"Net income","value":"Net loss per share, basic and diluted was $1.21 and $10.70 for the fourth quarter and full year ended December 31, 2025,"},{"label":"EPS","value":"Net loss per share, basic and diluted was $1.21 and $10.70 for the fourth quarter and full year ended December 31, 2025,"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}